25 XP   0   0   10

Mayne Pharma Group Ltd
Buy, Hold or Sell?

Let's analyse Mayne Pharma Group Ltd together

PenkeI guess you are interested in Mayne Pharma Group Ltd. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Mayne Pharma Group Ltd. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Mayne Pharma Group Ltd

I send you an email if I find something interesting about Mayne Pharma Group Ltd.

Quick analysis of Mayne Pharma Group Ltd (30 sec.)










What can you expect buying and holding a share of Mayne Pharma Group Ltd? (30 sec.)

How much money do you get?

How much money do you get?
A$0.46
When do you have the money?
1 year
How often do you get paid?
10.3%

What is your share worth?

Current worth
A$6.44
Expected worth in 1 year
A$-1.98
How sure are you?
33.3%

+ What do you gain per year?

Total Gains per Share
A$-7.71
Return On Investment
-106.4%

For what price can you sell your share?

Current Price per Share
A$7.24
Expected price per share
A$6.3613 - A$8.4486408450704
How sure are you?
50%

1. Valuation of Mayne Pharma Group Ltd (5 min.)




Live pricePrice per Share (EOD)

A$7.24

Intrinsic Value Per Share

A$-30.40 - A$-20.77

Total Value Per Share

A$-23.96 - A$-14.33

2. Growth of Mayne Pharma Group Ltd (5 min.)




Is Mayne Pharma Group Ltd growing?

Current yearPrevious yearGrowGrow %
How rich?$357.3m$535.4m-$140.5m-35.6%

How much money is Mayne Pharma Group Ltd making?

Current yearPrevious yearGrowGrow %
Making money-$73.1m-$86.1m$13m17.8%
Net Profit Margin-158.2%-90.9%--

How much money comes from the company's main activities?

3. Financial Health of Mayne Pharma Group Ltd (5 min.)




What can you expect buying and holding a share of Mayne Pharma Group Ltd? (5 min.)

Welcome investor! Mayne Pharma Group Ltd's management wants to use your money to grow the business. In return you get a share of Mayne Pharma Group Ltd.

What can you expect buying and holding a share of Mayne Pharma Group Ltd?

First you should know what it really means to hold a share of Mayne Pharma Group Ltd. And how you can make/lose money.

Speculation

The Price per Share of Mayne Pharma Group Ltd is A$7.24. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Mayne Pharma Group Ltd.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Mayne Pharma Group Ltd, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is A$6.44. Based on the TTM, the Book Value Change Per Share is A$-2.10 per quarter. Based on the YOY, the Book Value Change Per Share is A$1.00 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is A$0.18 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Mayne Pharma Group Ltd.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 A$% of Price per ShareA$% of Price per ShareA$% of Price per ShareA$% of Price per ShareA$% of Price per Share
Usd Eps-0.54-7.5%-0.84-11.6%0.436.0%-0.35-4.9%-0.18-2.5%
Usd Book Value Change Per Share-0.66-9.2%-1.37-19.0%0.659.0%-0.30-4.1%0.081.1%
Usd Dividend Per Share0.000.0%0.121.6%0.091.2%0.040.5%0.020.2%
Usd Total Gains Per Share-0.66-9.2%-1.26-17.4%0.7410.2%-0.26-3.6%0.101.4%
Usd Price Per Share4.01-3.11-0.16-0.69-0.70-
Price to Earnings Ratio-1.85--1.11--0.01--0.42-2.32-
Price-to-Total Gains Ratio-6.04-3.25--0.10-1.02-0.56-
Price to Book Ratio0.96-0.68-0.03-0.14-0.17-
Price-to-Total Gains Ratio-6.04-3.25--0.10-1.02-0.56-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share4.722652
Number of shares211
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.120.04
Usd Book Value Change Per Share-1.37-0.30
Usd Total Gains Per Share-1.26-0.26
Gains per Quarter (211 shares)-265.12-55.47
Gains per Year (211 shares)-1,060.50-221.89
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
198-1158-107031-253-232
2195-2316-213062-505-454
3293-3475-319093-758-676
4391-4633-4250123-1011-898
5488-5791-5310154-1264-1120
6586-6949-6370185-1516-1342
7684-8107-7430216-1769-1564
8782-9266-8490247-2022-1786
9879-10424-9550278-2275-2008
10977-11582-10610309-2527-2230

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.03.00.00.0%2.09.00.018.2%2.017.00.010.5%20.019.00.051.3%33.035.01.047.8%
Book Value Change Per Share0.02.01.00.0%2.05.04.018.2%3.09.07.015.8%11.013.015.028.2%23.020.026.033.3%
Dividend per Share2.00.01.066.7%4.00.07.036.4%4.00.015.021.1%4.00.035.010.3%9.00.060.013.0%
Total Gains per Share1.02.00.033.3%4.05.02.036.4%5.09.05.026.3%13.013.013.033.3%29.018.022.042.0%

Fundamentals of Mayne Pharma Group Ltd

About Mayne Pharma Group Ltd

Mayne Pharma Group Limited, a specialty pharmaceutical company, manufactures and sells branded and generic pharmaceutical products in Australia, New Zealand, the United States, Canada, Europe, Asia, and internationally. The company operates through four segments: International Branded Products, and Portfolio Product Division. It provides oral drug delivery systems; and contract development and manufacturing services to third-party customers, as well as distributes specialty pharmaceutical products in the dermatology, women's health, and infectious disease therapeutic areas. The company was formerly known as Halcygen Pharmaceuticals Limited and changed its name to Mayne Pharma Group Limited in November 2010. Mayne Pharma Group Limited was incorporated in 2005 and is based in Salisbury South, Australia.

Fundamental data was last updated by Penke on 2024-03-11 06:44:05.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is able to pay all its debts by selling its assets.
The company is able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is cheap.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is cheap.

1.1. Profitability of Mayne Pharma Group Ltd.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Mayne Pharma Group Ltd earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Mayne Pharma Group Ltd to the Drug Manufacturers - General industry mean.
  • A Net Profit Margin of -37.5% means that $-0.38 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Mayne Pharma Group Ltd:

  • The MRQ is -37.5%. The company is making a huge loss. -2
  • The TTM is -158.2%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-37.5%TTM-158.2%+120.6%
TTM-158.2%YOY-90.9%-67.2%
TTM-158.2%5Y-61.1%-97.1%
5Y-61.1%10Y-30.3%-30.8%
1.1.2. Return on Assets

Shows how efficient Mayne Pharma Group Ltd is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Mayne Pharma Group Ltd to the Drug Manufacturers - General industry mean.
  • -6.1% Return on Assets means that Mayne Pharma Group Ltd generated $-0.06 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Mayne Pharma Group Ltd:

  • The MRQ is -6.1%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -9.1%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-6.1%TTM-9.1%+3.0%
TTM-9.1%YOY-9.7%+0.6%
TTM-9.1%5Y-5.3%-3.9%
5Y-5.3%10Y-2.5%-2.7%
1.1.3. Return on Equity

Shows how efficient Mayne Pharma Group Ltd is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Mayne Pharma Group Ltd to the Drug Manufacturers - General industry mean.
  • -12.9% Return on Equity means Mayne Pharma Group Ltd generated $-0.13 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Mayne Pharma Group Ltd:

  • The MRQ is -12.9%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -20.1%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-12.9%TTM-20.1%+7.2%
TTM-20.1%YOY-22.3%+2.2%
TTM-20.1%5Y-11.1%-8.9%
5Y-11.1%10Y-5.3%-5.9%

1.2. Operating Efficiency of Mayne Pharma Group Ltd.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Mayne Pharma Group Ltd is operating .

  • Measures how much profit Mayne Pharma Group Ltd makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Mayne Pharma Group Ltd to the Drug Manufacturers - General industry mean.
  • An Operating Margin of -20.7% means the company generated $-0.21  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Mayne Pharma Group Ltd:

  • The MRQ is -20.7%. The company is operating very inefficient. -2
  • The TTM is -58.6%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-20.7%TTM-58.6%+37.9%
TTM-58.6%YOY-64.0%+5.4%
TTM-58.6%5Y-34.7%-23.9%
5Y-34.7%10Y-13.6%-21.1%
1.2.2. Operating Ratio

Measures how efficient Mayne Pharma Group Ltd is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Drug Manufacturers - General industry mean).
  • An Operation Ratio of 1.21 means that the operating costs are $1.21 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Mayne Pharma Group Ltd:

  • The MRQ is 1.207. The company is inefficient in keeping operating costs low. -1
  • The TTM is 1.747. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ1.207TTM1.747-0.541
TTM1.747YOY1.495+0.252
TTM1.7475Y1.064+0.683
5Y1.06410Y0.831+0.233

1.3. Liquidity of Mayne Pharma Group Ltd.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Mayne Pharma Group Ltd is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Drug Manufacturers - General industry mean).
  • A Current Ratio of 1.61 means the company has $1.61 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Mayne Pharma Group Ltd:

  • The MRQ is 1.608. The company is able to pay all its short-term debts. +1
  • The TTM is 1.723. The company is able to pay all its short-term debts. +1
Trends
Current periodCompared to+/- 
MRQ1.608TTM1.723-0.115
TTM1.723YOY1.146+0.577
TTM1.7235Y1.826-0.103
5Y1.82610Y1.586+0.240
1.3.2. Quick Ratio

Measures if Mayne Pharma Group Ltd is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Mayne Pharma Group Ltd to the Drug Manufacturers - General industry mean.
  • A Quick Ratio of 1.04 means the company can pay off $1.04 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Mayne Pharma Group Ltd:

  • The MRQ is 1.042. The company is just able to pay all its short-term debts with the most liquid assets.
  • The TTM is 1.526. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ1.042TTM1.526-0.484
TTM1.526YOY0.870+0.657
TTM1.5265Y1.209+0.317
5Y1.20910Y1.143+0.066

1.4. Solvency of Mayne Pharma Group Ltd.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Mayne Pharma Group Ltd assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Mayne Pharma Group Ltd to Drug Manufacturers - General industry mean.
  • A Debt to Asset Ratio of 0.53 means that Mayne Pharma Group Ltd assets are financed with 52.5% credit (debt) and the remaining percentage (100% - 52.5%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Mayne Pharma Group Ltd:

  • The MRQ is 0.525. The company is able to pay all its debts by selling its assets. +1
  • The TTM is 0.503. The company is able to pay all its debts by selling its assets. +1
Trends
Current periodCompared to+/- 
MRQ0.525TTM0.503+0.023
TTM0.503YOY0.421+0.082
TTM0.5035Y0.445+0.058
5Y0.44510Y0.424+0.021
1.4.2. Debt to Equity Ratio

Measures if Mayne Pharma Group Ltd is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Mayne Pharma Group Ltd to the Drug Manufacturers - General industry mean.
  • A Debt to Equity ratio of 110.6% means that company has $1.11 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Mayne Pharma Group Ltd:

  • The MRQ is 1.106. The company is able to pay all its debts with equity. +1
  • The TTM is 1.131. The company is able to pay all its debts with equity. +1
Trends
Current periodCompared to+/- 
MRQ1.106TTM1.131-0.025
TTM1.131YOY0.966+0.166
TTM1.1315Y0.882+0.249
5Y0.88210Y0.866+0.016

2. Market Valuation of Mayne Pharma Group Ltd

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Mayne Pharma Group Ltd generates.

  • Above 15 is considered overpriced but always compare Mayne Pharma Group Ltd to the Drug Manufacturers - General industry mean.
  • A PE ratio of -1.85 means the investor is paying $-1.85 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Mayne Pharma Group Ltd:

  • The EOD is -2.183. Based on the earnings, the company is expensive. -2
  • The MRQ is -1.854. Based on the earnings, the company is expensive. -2
  • The TTM is -1.106. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-2.183MRQ-1.854-0.329
MRQ-1.854TTM-1.106-0.748
TTM-1.106YOY-0.012-1.095
TTM-1.1065Y-0.419-0.688
5Y-0.41910Y2.318-2.736
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Mayne Pharma Group Ltd:

  • The EOD is -3.721. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -3.160. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is 11.075. Based on how much money comes from the company's main activities, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD-3.721MRQ-3.160-0.560
MRQ-3.160TTM11.075-14.235
TTM11.075YOY-0.334+11.409
TTM11.0755Y2.280+8.795
5Y2.28010Y-0.410+2.690
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Mayne Pharma Group Ltd is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Drug Manufacturers - General industry mean).
  • A PB ratio of 0.96 means the investor is paying $0.96 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Mayne Pharma Group Ltd:

  • The EOD is 1.124. Based on the equity, the company is underpriced. +1
  • The MRQ is 0.955. Based on the equity, the company is cheap. +2
  • The TTM is 0.683. Based on the equity, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD1.124MRQ0.955+0.169
MRQ0.955TTM0.683+0.272
TTM0.683YOY0.029+0.654
TTM0.6835Y0.137+0.546
5Y0.13710Y0.175-0.038
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Mayne Pharma Group Ltd.

3.1. Funds holding Mayne Pharma Group Ltd

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Mayne Pharma Group Ltd compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---1.018-2.104+107%0.996-202%-0.459-55%0.125-916%
Book Value Per Share--6.4397.117-10%9.591-33%10.050-36%9.556-33%
Current Ratio--1.6081.723-7%1.146+40%1.826-12%1.586+1%
Debt To Asset Ratio--0.5250.503+4%0.421+25%0.445+18%0.424+24%
Debt To Equity Ratio--1.1061.131-2%0.966+15%0.882+25%0.866+28%
Dividend Per Share---0.177-100%0.133-100%0.056-100%0.027-100%
Eps---0.829-1.292+56%0.664-225%-0.543-35%-0.282-66%
Free Cash Flow Per Share---0.486-0.125-74%-0.968+99%-0.221-55%-0.380-22%
Free Cash Flow To Equity Per Share---0.765-0.582-24%-2.438+219%-0.510-33%-0.292-62%
Gross Profit Margin--1.0001.229-19%1.289-22%1.294-23%0.825+21%
Intrinsic Value_10Y_max---20.768--------
Intrinsic Value_10Y_min---30.398--------
Intrinsic Value_1Y_max---1.603--------
Intrinsic Value_1Y_min---1.819--------
Intrinsic Value_3Y_max---5.180--------
Intrinsic Value_3Y_min---6.561--------
Intrinsic Value_5Y_max---9.197--------
Intrinsic Value_5Y_min---12.466--------
Market Cap615937960.960+15%523206969.600405520849.067+29%20934845.100+2399%90209370.423+480%91687927.720+471%
Net Profit Margin---0.375-1.582+321%-0.909+142%-0.611+63%-0.303-19%
Operating Margin---0.207-0.586+184%-0.640+210%-0.347+68%-0.136-34%
Operating Ratio--1.2071.747-31%1.495-19%1.064+13%0.831+45%
Pb Ratio1.124+15%0.9550.683+40%0.029+3221%0.137+597%0.175+446%
Pe Ratio-2.183-18%-1.854-1.106-40%-0.012-99%-0.419-77%2.318-180%
Price Per Share7.240+15%6.1504.767+29%0.244+2423%1.059+481%1.077+471%
Price To Free Cash Flow Ratio-3.721-18%-3.16011.075-129%-0.334-89%2.280-239%-0.410-87%
Price To Total Gains Ratio-7.114-18%-6.0433.247-286%-0.096-98%1.018-694%0.560-1179%
Quick Ratio--1.0421.526-32%0.870+20%1.209-14%1.143-9%
Return On Assets---0.061-0.091+50%-0.097+59%-0.053-14%-0.025-58%
Return On Equity---0.129-0.201+56%-0.223+73%-0.111-13%-0.053-59%
Total Gains Per Share---1.018-1.926+89%1.129-190%-0.403-60%0.152-769%
Usd Book Value--357312327.900394966127.967-10%535478614.550-33%560330403.426-36%531562280.615-33%
Usd Book Value Change Per Share---0.664-1.372+107%0.650-202%-0.299-55%0.081-916%
Usd Book Value Per Share--4.2004.643-10%6.256-33%6.556-36%6.233-33%
Usd Dividend Per Share---0.116-100%0.087-100%0.037-100%0.018-100%
Usd Eps---0.541-0.843+56%0.433-225%-0.354-35%-0.184-66%
Usd Free Cash Flow---26997391.748-6927425.783-74%-53810346.975+99%-12294207.050-54%-21087922.347-22%
Usd Free Cash Flow Per Share---0.317-0.081-74%-0.631+99%-0.144-55%-0.248-22%
Usd Free Cash Flow To Equity Per Share---0.499-0.380-24%-1.590+219%-0.333-33%-0.191-62%
Usd Market Cap401776331.934+15%341287906.270264521249.846+29%13655799.459+2399%58843572.327+480%59808035.252+471%
Usd Price Per Share4.723+15%4.0123.109+29%0.159+2423%0.691+481%0.702+471%
Usd Profit---46021069.600-73173057.100+59%-86197367.962+87%-48223715.008+5%-25199310.708-45%
Usd Revenue--122584129.80067742985.750+81%61986356.713+98%72854803.363+68%65758066.120+86%
Usd Total Gains Per Share---0.664-1.257+89%0.737-190%-0.263-60%0.099-769%
 EOD+5 -3MRQTTM+19 -17YOY+19 -175Y+9 -2710Y+8 -28

4.2. Fundamental Score

Let's check the fundamental score of Mayne Pharma Group Ltd based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-2.183
Price to Book Ratio (EOD)Between0-11.124
Net Profit Margin (MRQ)Greater than0-0.375
Operating Margin (MRQ)Greater than0-0.207
Quick Ratio (MRQ)Greater than11.042
Current Ratio (MRQ)Greater than11.608
Debt to Asset Ratio (MRQ)Less than10.525
Debt to Equity Ratio (MRQ)Less than11.106
Return on Equity (MRQ)Greater than0.15-0.129
Return on Assets (MRQ)Greater than0.05-0.061
Total3/10 (30.0%)

4.3. Technical Score

Let's check the technical score of Mayne Pharma Group Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5069.113
Ma 20Greater thanMa 506.965
Ma 50Greater thanMa 1006.061
Ma 100Greater thanMa 2005.702
OpenGreater thanClose7.300
Total5/5 (100.0%)



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in AUD. All numbers in thousands.

Summary
Total Assets1,153,691
Total Liabilities605,918
Total Stockholder Equity547,773
 As reported
Total Liabilities 605,918
Total Stockholder Equity+ 547,773
Total Assets = 1,153,691

Assets

Total Assets1,153,691
Total Current Assets475,303
Long-term Assets678,388
Total Current Assets
Cash And Cash Equivalents 109,227
Net Receivables 198,863
Inventory 91,904
Other Current Assets 75,309
Total Current Assets  (as reported)475,303
Total Current Assets  (calculated)475,303
+/-0
Long-term Assets
Property Plant Equipment 50,353
Long-term Assets Other 600,121
Long-term Assets  (as reported)678,388
Long-term Assets  (calculated)650,474
+/- 27,914

Liabilities & Shareholders' Equity

Total Current Liabilities295,658
Long-term Liabilities310,260
Total Stockholder Equity547,773
Total Current Liabilities
Short-term Debt 3,468
Accounts payable 42,774
Other Current Liabilities 242,318
Total Current Liabilities  (as reported)295,658
Total Current Liabilities  (calculated)288,560
+/- 7,098
Long-term Liabilities
Long-term Liabilities  (as reported)310,260
Long-term Liabilities  (calculated)0
+/- 310,260
Total Stockholder Equity
Common Stock1,223,920
Retained Earnings -840,322
Accumulated Other Comprehensive Income 164,175
Total Stockholder Equity (as reported)547,773
Total Stockholder Equity (calculated)547,773
+/-0
Other
Cash and Short Term Investments 109,227
Common Stock Shares Outstanding 81,246
Current Deferred Revenue7,098
Liabilities and Stockholders Equity 1,153,691
Net Debt -72,652
Net Working Capital 179,645
Short Long Term Debt Total 36,575



Balance Sheet

Currency in AUD. All numbers in thousands.

 Trend2023-12-312023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312010-09-302010-06-302010-03-312009-12-312009-09-302009-06-302009-03-312008-12-312008-09-302008-06-302008-03-312007-12-312007-09-302007-06-302007-03-312006-12-312006-09-302006-06-30
> Total Assets 
29
3,906
3,906
15,511
15,510
13,419
13,419
11,693
11,693
9,504
9,504
8,036
8,036
60,634
60,634
71,148
71,149
63,759
63,759
53,677
53,677
55,401
55,401
50,203
53,933
189,664
189,664
233,391
233,391
256,624
256,624
265,820
265,820
319,941
319,941
528,946
528,946
601,210
601,210
1,525,782
1,557,381
1,947,941
1,947,941
1,908,037
1,914,920
1,729,990
1,729,990
1,830,508
1,830,507
2,012,493
2,012,493
1,636,333
1,636,333
1,868,944
1,868,944
0
1,825,180
0
1,486,966
0
1,463,184
0
1,467,852
1,287,926
1,287,926
1,493,586
1,493,586
1,247,354
1,247,354
1,153,691
1,153,6911,247,3541,247,3541,493,5861,493,5861,287,9261,287,9261,467,85201,463,18401,486,96601,825,18001,868,9441,868,9441,636,3331,636,3332,012,4932,012,4931,830,5071,830,5081,729,9901,729,9901,914,9201,908,0371,947,9411,947,9411,557,3811,525,782601,210601,210528,946528,946319,941319,941265,820265,820256,624256,624233,391233,391189,664189,66453,93350,20355,40155,40153,67753,67763,75963,75971,14971,14860,63460,6348,0368,0369,5049,50411,69311,69313,41913,41915,51015,5113,9063,90629
   > Total Current Assets 
0
0
0
0
15,453
0
0
0
11,648
0
0
0
8,013
0
0
0
32,529
0
0
0
18,838
0
0
0
23,255
0
0
0
61,909
0
0
0
65,895
0
0
0
156,820
0
0
0
1,108,650
426,635
426,635
429,003
429,003
420,892
420,892
480,767
480,767
531,786
531,786
471,946
471,946
440,449
440,449
490,947
490,947
465,888
465,888
416,528
416,528
467,734
467,734
511,618
511,618
594,689
594,689
553,629
553,629
475,303
475,303553,629553,629594,689594,689511,618511,618467,734467,734416,528416,528465,888465,888490,947490,947440,449440,449471,946471,946531,786531,786480,767480,767420,892420,892429,003429,003426,635426,6351,108,650000156,82000065,89500061,90900023,25500018,83800032,5290008,01300011,64800015,4530000
       Cash And Cash Equivalents 
0
0
0
0
15,303
0
0
0
11,531
0
0
0
7,936
0
0
0
19,709
0
0
0
5,807
0
0
0
11,596
0
0
0
18,938
0
0
0
14,813
0
0
0
59,201
0
0
0
47,481
80,820
80,820
63,027
63,027
55,957
55,957
87,312
87,312
96,173
96,173
89,004
89,004
98,529
98,529
0
137,785
0
131,535
0
97,980
0
114,733
96,672
96,672
175,541
175,541
92,616
92,616
109,227
109,22792,61692,616175,541175,54196,67296,672114,733097,9800131,5350137,785098,52998,52989,00489,00496,17396,17387,31287,31255,95755,95763,02763,02780,82080,82047,48100059,20100014,81300018,93800011,5960005,80700019,7090007,93600011,53100015,3030000
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
65
0
0
0
1,825
0
0
0
1,172
0
0
0
2,229
0
0
0
3,458
2,197
2,197
6,208
6,208
5,579
5,579
8,316
6,747
742
742
563
563
734
734
0
443
0
2,743
0
2,733
0
2,478
127,526
2,426
0
412
127,526
127,526
0
0127,526127,52641202,426127,5262,47802,73302,743044307347345635637427426,7478,3165,5795,5796,2086,2082,1972,1973,4580002,2290001,1720001,82500065000000000000000000000000
       Net Receivables 
0
4
4
80
80
62
62
47
47
49
49
39
39
6,083
6,083
5,999
5,999
7,768
7,768
6,327
5,697
8,895
8,895
3,821
3,821
20,786
20,786
26,853
24,622
29,931
29,931
31,311
29,805
29,640
29,640
68,209
64,657
102,372
102,372
99,679
123,716
215,028
215,028
233,842
232,716
249,475
235,970
274,921
252,715
305,358
298,302
257,103
256,580
219,822
219,822
233,269
195,908
208,656
208,656
193,338
183,283
214,523
214,523
268,241
268,241
260,903
233,799
209,517
194,887
198,863
198,863194,887209,517233,799260,903268,241268,241214,523214,523183,283193,338208,656208,656195,908233,269219,822219,822256,580257,103298,302305,358252,715274,921235,970249,475232,716233,842215,028215,028123,71699,679102,372102,37264,65768,20929,64029,64029,80531,31129,93129,93124,62226,85320,78620,7863,8213,8218,8958,8955,6976,3277,7687,7685,9995,9996,0836,08339394949474762628080440
       Other Current Assets 
0
10
10
70
70
69
69
71
70
28
28
37
37
777
777
321
321
592
592
281
911
779
779
594
529
1,047
1,047
1,335
2,931
1,044
1,044
1,846
2,869
1,937
1,937
5,333
8,289
8,967
8,967
887,653
895,052
16,862
16,862
10,869
20,658
17,760
17,760
365
51,837
0
25,622
398
398
0
28,023
409
443
30,291
30,291
13,849
16,208
26,595
26,595
12,134
37,797
32,929
32,517
28,173
28,173
75,309
75,30928,17328,17332,51732,92937,79712,13426,59526,59516,20813,84930,29130,29144340928,023039839825,622051,83736517,76017,76020,65810,86916,86216,862895,052887,6538,9678,9678,2895,3331,9371,9372,8691,8461,0441,0442,9311,3351,0471,0475295947797799112815925923213217777773737282870716969707010100
   > Long-term Assets 
0
0
0
0
57
0
0
0
45
0
0
0
23
0
0
0
38,621
0
0
0
34,839
0
0
0
30,678
0
0
0
171,482
0
0
0
199,925
0
0
0
372,126
0
0
0
448,731
0
0
0
1,485,917
0
0
0
1,349,740
0
0
0
1,164,387
0
0
0
1,334,233
0
0
0
1,046,656
0
0
776,308
776,308
778,598
778,598
666,707
693,725
678,388
678,388693,725666,707778,598778,598776,308776,308001,046,6560001,334,2330001,164,3870001,349,7400001,485,917000448,731000372,126000199,925000171,48200030,67800034,83900038,6210002300045000570000
       Property Plant Equipment 
0
0
0
57
57
57
57
45
45
37
37
23
23
19,347
19,347
21,047
21,047
21,275
21,275
21,457
21,457
22,238
22,238
22,224
22,224
56,200
56,200
55,036
55,036
55,593
55,593
53,409
53,409
57,028
57,028
59,597
59,597
65,373
65,373
84,449
84,449
142,336
142,336
189,272
189,272
212,226
212,226
230,051
230,051
237,979
237,979
236,034
236,034
242,894
242,894
238,244
238,244
215,071
215,071
221,595
221,595
220,883
220,883
225,855
225,855
50,141
50,141
51,482
51,482
50,353
50,35351,48251,48250,14150,141225,855225,855220,883220,883221,595221,595215,071215,071238,244238,244242,894242,894236,034236,034237,979237,979230,051230,051212,226212,226189,272189,272142,336142,33684,44984,44965,37365,37359,59759,59757,02857,02853,40953,40955,59355,59355,03655,03656,20056,20022,22422,22422,23822,23821,45721,45721,27521,27521,04721,04719,34719,34723233737454557575757000
       Goodwill 
0
0
0
0
0
0
0
0
0
0
0
0
0
13,320
13,320
391
391
0
0
391
391
0
0
391
391
391
391
47,197
47,197
50,483
50,483
47,476
47,476
54,689
54,689
58,436
58,436
61,290
61,290
60,115
60,115
61,897
61,897
58,217
58,217
19,583
19,583
20,616
20,616
21,629
21,629
21,725
21,725
21,752
21,752
0
22,174
0
19,826
0
20,346
0
21,020
22,127
22,127
0
0
0
0
0
0000022,12722,12721,020020,346019,826022,174021,75221,75221,72521,72521,62921,62920,61620,61619,58319,58358,21758,21761,89761,89760,11560,11561,29061,29058,43658,43654,68954,68947,47647,47650,48350,48347,19747,197391391391391003913910039139113,32013,3200000000000000
       Intangible Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
13,320
13,320
14,226
13,835
11,225
11,225
8,183
7,792
6,279
6,279
4,194
3,803
3,228
3,228
97,465
68,273
104,080
104,080
107,677
93,639
140,479
140,479
251,398
244,524
258,470
258,470
260,435
272,368
1,212,873
1,212,873
1,143,830
1,177,224
932,570
999,020
931,685
1,033,910
1,041,287
1,157,176
722,534
775,907
968,385
1,026,173
0
940,117
0
623,660
0
615,808
0
550,731
405,387
405,387
728,457
728,457
615,225
617,264
0
0617,264615,225728,457728,457405,387405,387550,7310615,8080623,6600940,11701,026,173968,385775,907722,5341,157,1761,041,2871,033,910931,685999,020932,5701,177,2241,143,8301,212,8731,212,873272,368260,435258,470258,470244,524251,398140,479140,47993,639107,677104,080104,08068,27397,4653,2283,2283,8034,1946,2796,2797,7928,18311,22511,22513,83514,22613,32013,3200000000000000
       Other Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
14,612
14,612
17,573
17,573
14,516
14,516
13,382
13,382
10,638
10,638
4,724
8,454
68,817
68,817
116,446
116,446
132,753
132,753
146,516
146,516
191,479
191,479
312,529
312,529
344,489
344,489
364,282
364,282
1,378,970
1,378,970
1,296,645
1,296,645
1,096,872
78,269
167,389
65,164
179,812
63,923
184,094
130,126
195,464
195,464
174,398
174,398
181,776
181,776
-302,376
-302,376
222,556
222,556
-606,224
-606,224
120,299
120,299
27,018
24,979
0
024,97927,018120,299120,299-606,224-606,224222,556222,556-302,376-302,376181,776181,776174,398174,398195,464195,464130,126184,09463,923179,81265,164167,38978,2691,096,8721,296,6451,296,6451,378,9701,378,970364,282364,282344,489344,489312,529312,529191,479191,479146,516146,516132,753132,753116,446116,44668,81768,8178,4544,72410,63810,63813,38213,38214,51614,51617,57317,57314,61214,6120000000000000
> Total Liabilities 
8
183
183
996
996
323
323
255
255
279
279
332
332
41,280
41,280
45,599
45,600
39,289
39,289
29,503
29,503
27,173
27,173
19,603
23,333
82,503
82,503
112,502
112,502
122,825
122,825
106,546
106,546
139,937
139,937
206,744
206,744
249,057
249,057
1,149,561
1,181,160
577,280
577,280
595,613
602,496
596,850
606,420
595,351
595,350
715,087
722,658
622,258
622,258
773,074
778,330
0
782,867
0
715,854
0
691,605
0
722,098
730,806
730,806
408,889
408,889
612,994
612,994
605,918
605,918612,994612,994408,889408,889730,806730,806722,0980691,6050715,8540782,8670778,330773,074622,258622,258722,658715,087595,350595,351606,420596,850602,496595,613577,280577,2801,181,1601,149,561249,057249,057206,744206,744139,937139,937106,546106,546122,825122,825112,502112,50282,50382,50323,33319,60327,17327,17329,50329,50339,28939,28945,60045,59941,28041,2803323322792792552553233239969961831838
   > Total Current Liabilities 
8
183
183
991
991
319
319
253
253
279
279
318
318
13,953
13,953
23,167
23,167
18,219
18,219
14,939
14,939
12,150
12,150
12,304
12,304
30,591
30,591
42,111
42,111
35,654
35,654
30,379
30,379
54,586
54,586
95,078
95,078
132,013
132,013
1,024,325
1,055,924
209,596
209,596
193,012
199,895
186,130
186,130
179,897
179,897
267,249
267,249
211,329
211,329
199,096
199,096
219,253
219,253
249,684
249,684
222,527
222,527
228,904
228,904
610,421
610,421
408,889
408,889
310,959
310,959
295,658
295,658310,959310,959408,889408,889610,421610,421228,904228,904222,527222,527249,684249,684219,253219,253199,096199,096211,329211,329267,249267,249179,897179,897186,130186,130199,895193,012209,596209,5961,055,9241,024,325132,013132,01395,07895,07854,58654,58630,37930,37935,65435,65442,11142,11130,59130,59112,30412,30412,15012,15014,93914,93918,21918,21923,16723,16713,95313,9533183182792792532533193199919911831838
       Short-term Debt 
0
0
0
0
3
0
0
0
3
0
0
0
2
0
0
0
7,587
0
0
0
2,339
0
0
0
65
0
0
0
7,471
0
0
0
2,374
0
0
0
2,229
0
0
0
503
313,447
313,447
340,246
13,124
359,094
359,094
374,190
58
0
35,538
437
50,881
1,008
41,446
0
44,836
0
46,407
0
54,043
0
51,778
407,993
407,993
0
73,845
0
14,427
3,468
3,46814,427073,8450407,993407,99351,778054,043046,407044,836041,4461,00850,88143735,538058374,190359,094359,09413,124340,246313,447313,4475030002,2290002,3740007,471000650002,3390007,5870002000300030000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
313,447
313,447
340,246
340,246
359,094
359,094
374,190
374,190
0
0
437
50,861
1,008
1,008
0
44,836
0
0
0
51,158
0
0
0
405,367
0
0
0
10,810
0
010,810000405,36700051,15800044,83601,0081,00850,86143700374,190374,190359,094359,094340,246340,246313,447313,44700000000000000000000000000000000000000000
       Accounts payable 
8
183
183
166
166
305
305
135
135
229
229
119
119
3,611
3,611
2,227
2,227
4,472
4,472
2,142
2,142
4,855
4,855
2,893
2,893
7,866
7,866
6,832
6,832
14,120
14,120
7,131
7,131
14,655
14,655
51,572
51,572
111,602
111,602
64,051
135,508
72,730
72,730
66,593
66,593
58,336
58,336
63,888
63,888
57,548
57,548
50,443
50,443
40,826
40,826
29,842
29,842
43,778
43,778
42,363
42,363
46,260
46,260
63,571
63,571
49,634
49,634
32,027
32,027
42,774
42,77432,02732,02749,63449,63463,57163,57146,26046,26042,36342,36343,77843,77829,84229,84240,82640,82650,44350,44357,54857,54863,88863,88858,33658,33666,59366,59372,73072,730135,50864,051111,602111,60251,57251,57214,65514,6557,1317,13114,12014,1206,8326,8327,8667,8662,8932,8934,8554,8552,1422,1424,4724,4722,2272,2273,6113,6111191192292291351353053051661661831838
       Other Current Liabilities 
0
0
0
824
821
14
14
118
115
49
49
199
197
4,743
4,743
13,353
13,353
8,873
8,873
10,458
10,458
7,295
7,295
9,411
9,411
20,044
20,044
27,808
27,808
15,319
15,319
20,874
20,874
31,736
31,736
43,506
43,506
20,411
20,411
959,771
919,913
136,494
136,494
113,295
120,178
127,787
127,787
37,526
115,951
50,313
50,313
41,124
13,922
48,742
48,742
70,599
49,293
68,484
68,484
61,260
36,080
65,949
65,949
138,857
138,857
359,255
359,255
278,932
22,854
242,318
242,31822,854278,932359,255359,255138,857138,85765,94965,94936,08061,26068,48468,48449,29370,59948,74248,74213,92241,12450,31350,313115,95137,526127,787127,787120,178113,295136,494136,494919,913959,77120,41120,41143,50643,50631,73631,73620,87420,87415,31915,31927,80827,80820,04420,0449,4119,4117,2957,29510,45810,4588,8738,87313,35313,3534,7434,74319719949491151181414821824000
   > Long-term Liabilities 
0
0
0
0
6
0
0
0
2
0
0
0
14
0
0
0
22,433
0
0
0
14,564
0
0
0
11,029
0
0
0
70,391
0
0
0
76,167
0
0
0
111,666
0
0
0
125,236
0
0
0
402,601
0
0
0
415,453
0
0
0
410,929
0
0
0
563,614
0
0
0
469,078
0
0
120,385
120,385
0
286,653
28,480
302,035
310,260
310,260302,03528,480286,6530120,385120,38500469,078000563,614000410,929000415,453000402,601000125,236000111,66600076,16700070,39100011,02900014,56400022,43300014000200060000
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
359,087
0
374,132
0
337,775
0
318,501
0
343,388
0
353,211
0
287,409
0
292,776
0
332,695
0
5,673
0
4,337
0
33,078
0
033,07804,33705,6730332,6950292,7760287,4090353,2110343,3880318,5010337,7750374,1320359,0870000000000000000000000000000000000000000000000
       Other Liabilities 
0
0
0
6
6
4
4
2
2
1
1
14
14
21,904
21,904
15,856
15,856
16,141
16,141
10,086
10,086
10,510
10,510
7,299
7,299
9,109
9,109
10,594
10,594
15,242
15,242
8,726
8,726
8,785
8,785
8,557
8,557
7,206
7,206
7,265
7,265
6,421
6,421
18,567
18,567
16,949
16,949
41,322
41,322
110,063
110,063
92,428
92,428
230,590
230,590
210,403
210,403
175,374
175,374
176,302
176,302
157,392
157,392
114,712
114,712
282,166
282,166
268,957
268,957
0
0268,957268,957282,166282,166114,712114,712157,392157,392176,302176,302175,374175,374210,403210,403230,590230,59092,42892,428110,063110,06341,32241,32216,94916,94918,56718,5676,4216,4217,2657,2657,2067,2068,5578,5578,7858,7858,7268,72615,24215,24210,59410,5949,1099,1097,2997,29910,51010,51010,08610,08616,14116,14115,85615,85621,90421,904141411224466000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
83,819
83,819
91,611
91,611
86,033
86,033
102,225
102,225
115,889
115,889
53,373
53,373
57,788
57,788
40,700
40,700
19,255
19,255
-491,283
-491,283
15,072
15,072
-729,163
-729,163
6,073
6,073
2,039
2,039
0
02,0392,0396,0736,073-729,163-729,16315,07215,072-491,283-491,28319,25519,25540,70040,70057,78857,78853,37353,373115,889115,889102,225102,22586,03386,03391,61191,61183,81983,81900000000000000000000000000000000000000000
> Total Stockholder Equity
21
3,724
3,724
14,514
14,514
13,096
13,096
11,438
11,438
9,224
9,224
7,704
7,704
19,354
19,354
25,549
25,550
24,470
24,470
24,174
24,174
28,228
28,228
30,600
30,600
107,161
107,161
120,889
120,889
133,799
133,799
159,274
159,274
180,004
180,004
310,870
310,870
341,578
341,578
363,749
363,749
1,358,060
1,358,060
1,303,838
1,303,838
1,123,570
1,123,570
1,226,464
1,226,464
1,289,835
1,289,835
1,007,766
1,007,766
1,090,614
1,090,614
0
1,037,547
0
771,112
0
768,357
0
745,754
564,773
564,773
641,539
641,539
463,922
634,360
547,773
547,773634,360463,922641,539641,539564,773564,773745,7540768,3570771,11201,037,54701,090,6141,090,6141,007,7661,007,7661,289,8351,289,8351,226,4641,226,4641,123,5701,123,5701,303,8381,303,8381,358,0601,358,060363,749363,749341,578341,578310,870310,870180,004180,004159,274159,274133,799133,799120,889120,889107,161107,16130,60030,60028,22828,22824,17424,17424,47024,47025,55025,54919,35419,3547,7047,7049,2249,22411,43811,43813,09613,09614,51414,5143,7243,72421
   Common Stock
30
4,074
4,074
15,908
15,908
15,869
15,869
15,869
15,869
15,869
15,869
15,869
15,869
28,689
28,689
29,649
29,649
30,883
30,883
31,870
31,870
32,016
32,016
32,016
32,016
113,234
113,234
118,302
118,302
119,717
119,717
137,498
137,498
137,726
137,726
255,834
255,834
258,712
258,712
263,161
263,161
1,125,331
1,125,331
1,130,404
1,130,404
1,129,725
1,129,725
1,131,761
1,131,761
1,139,615
1,139,615
1,140,008
1,140,008
1,238,081
1,238,081
1,238,584
1,238,584
1,238,584
1,238,584
1,238,537
1,238,537
1,238,537
1,238,537
1,238,537
1,238,537
1,238,537
1,238,537
1,233,692
1,233,692
1,223,920
1,223,9201,233,6921,233,6921,238,5371,238,5371,238,5371,238,5371,238,5371,238,5371,238,5371,238,5371,238,5841,238,5841,238,5841,238,5841,238,0811,238,0811,140,0081,140,0081,139,6151,139,6151,131,7611,131,7611,129,7251,129,7251,130,4041,130,4041,125,3311,125,331263,161263,161258,712258,712255,834255,834137,726137,726137,498137,498119,717119,717118,302118,302113,234113,23432,01632,01632,01632,01631,87031,87030,88330,88329,64929,64928,68928,68915,86915,86915,86915,86915,86915,86915,86915,86915,90815,9084,0744,07430
   Retained Earnings Total Equity0000000000000000000000000000000000000000000000000000000000000000000000
   Accumulated Other Comprehensive Income 
0
0
0
0
439
0
0
0
875
0
0
0
902
0
0
0
1,714
0
0
0
960
0
0
0
1,087
0
0
0
7,461
0
0
0
5,360
0
0
0
30,861
0
0
0
39,058
0
0
0
23,337
0
0
0
71,178
0
0
0
125,099
0
0
0
149,603
0
0
0
88,883
0
0
148,642
148,642
0
156,655
0
170,438
164,175
164,175170,4380156,6550148,642148,6420088,883000149,603000125,09900071,17800023,33700039,05800030,8610005,3600007,4610001,0870009600001,7140009020008750004390000
   Capital Surplus 0000000000000000000000000000000000000000000000000000000000000000000000
   Treasury Stock0000000000000000000000000000000000000000000000000000000000000000000000
   Other Stockholders Equity 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
98,463
98,463
23,337
23,337
10,542
-2,828
71,178
54,086
124,115
103,473
125,099
99,510
127,417
127,417
149,603
149,603
64,454
64,454
88,883
88,883
116,650
116,650
148,642
148,642
-641,539
-641,539
-463,922
-463,922
0
0-463,922-463,922-641,539-641,539148,642148,642116,650116,65088,88388,88364,45464,454149,603149,603127,417127,41799,510125,099103,473124,11554,08671,178-2,82810,54223,33723,33798,46398,46300000000000000000000000000000000000000000



Balance Sheet

Currency in AUD. All numbers in thousands.




Cash Flow

Currency in AUD. All numbers in thousands.




Income Statement

Currency in AUD. All numbers in thousands.


Latest Income Statement (annual, 2023-06-30)

Gross Profit (+$)
totalRevenue183,586
Cost of Revenue-156,748
Gross Profit26,83826,838
 
Operating Income (+$)
Gross Profit26,838
Operating Expense-213,282
Operating Income-186,444-186,444
 
Operating Expense (+$)
Research Development15,729
Selling General Administrative58,053
Selling And Marketing Expenses125,945
Operating Expense213,282199,727
 
Net Interest Income (+$)
Interest Income6,719
Interest Expense-10,454
Other Finance Cost-18,396
Net Interest Income-22,131
 
Pretax Income (+$)
Operating Income-186,444
Net Interest Income-22,131
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-269,698-103,190
EBIT - interestExpense = -196,898
-268,674
-305,965
Interest Expense10,454
Earnings Before Interest and Taxes (EBIT)-186,444-259,244
Earnings Before Interest and Taxes (EBITDA)-121,003
 
After tax Income (+$)
Income Before Tax-269,698
Tax Provision-50,426
Net Income From Continuing Ops-317,443-320,124
Net Income-316,419
Net Income Applicable To Common Shares117,249
 
Non-recurring Events
Discontinued Operations434,600
Extraordinary Items437,281
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses370,030
Total Other Income/Expenses Net-83,25422,131
 

Technical Analysis of Mayne Pharma Group Ltd
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Mayne Pharma Group Ltd. The general trend of Mayne Pharma Group Ltd is BULLISH with 100.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Mayne Pharma Group Ltd's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (100.0%) Bearish trend (-100.0%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Mayne Pharma Group Ltd.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is -1/(-1 +1).

  • Around resistance: The price is trading arround resistance levels. This can be considered as a potential exit level. -1

The bullish price targets are: 7.35 < 8.4486408450704.

The bearish price targets are: 6.59 > 6.42 > 6.3613.

Tweet this
Mayne Pharma Group Ltd Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Mayne Pharma Group Ltd. The current mas is .

The long score for the Moving Averages is 14/14.
The longshort score for the Moving Averages is 14/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Mayne Pharma Group Ltd Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Mayne Pharma Group Ltd. The current macd is 0.27087022.

The long score for the Moving Average Convergence/Divergence (MACD) is 2/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 0/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Mayne Pharma Group Ltd price going down in the near term. -2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for Mayne Pharma Group Ltd. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the Mayne Pharma Group Ltd price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Mayne Pharma Group Ltd Daily Moving Average Convergence/Divergence (MACD) ChartMayne Pharma Group Ltd Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Mayne Pharma Group Ltd. The current adx is 41.77.

The long score for the Directional Movement Index (DMI) is 4/7.
The longshort score for the Directional Movement Index (DMI) is 4/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Mayne Pharma Group Ltd shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX > 25 && ADX trending up: The ADX is above 25 and indicates a strong bullish trend. The ADX is trending up, so the bullish trend is strengthening.
Mayne Pharma Group Ltd Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Mayne Pharma Group Ltd. The current sar is 6.59.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
Mayne Pharma Group Ltd Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Mayne Pharma Group Ltd. The current rsi is 69.11. The current phase is Continuation in bull market.

The long score for the Relative Strength Index (RSI) is 4/13.
The longshort score for the Relative Strength Index (RSI) is 4/(-13 +13).

  • Continuation in bull market: Uptrend continues after a consolidation or pullback. Hold or add to existing positions.
  • Trending up: The RSI is trending up. +1
Mayne Pharma Group Ltd Daily Relative Strength Index (RSI) ChartMayne Pharma Group Ltd Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Mayne Pharma Group Ltd. The current phase is Overbought in bull market.

The long score for the Stochastic Oscillator is 5/6.
The longshort score for the Stochastic Oscillator is 4/(-6 +6).

  • STOCH > 50: The STOCH %K is above 50. There are more buyers than sellers. +1
  • STOCH > 80: The STOCH %K is above 80 and overbought. +2
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Mayne Pharma Group Ltd price going up in the near term. +2
  • Trending down: The STOCH %K is trending down. -1
Mayne Pharma Group Ltd Daily Stochastic Oscillator ChartMayne Pharma Group Ltd Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Mayne Pharma Group Ltd. The current cci is 186.56.

The long score for the Commodity Channel Index (CCI) is 1/1.
The longshort score for the Commodity Channel Index (CCI) is 1/(-1 +1).

  • CCI > 100: The CCI is above 100, it indicates that the price is significantly above its average, suggesting a potential overbought condition. +1
Mayne Pharma Group Ltd Daily Commodity Channel Index (CCI) ChartMayne Pharma Group Ltd Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Mayne Pharma Group Ltd. The current cmo is 41.47.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
Mayne Pharma Group Ltd Daily Chande Momentum Oscillator (CMO) ChartMayne Pharma Group Ltd Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Mayne Pharma Group Ltd. The current willr is -10.95890411.

The long score for the Williams %R is 1/1.
The longshort score for the Williams %R is 1/(-1 +1).

  • WILLR > -20: The Williams %R is above -20. This indicates that the price is in overbought territory, suggesting a potential price correction or trend reversal to the downside. +1
Mayne Pharma Group Ltd Daily Williams %R ChartMayne Pharma Group Ltd Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Mayne Pharma Group Ltd.

Mayne Pharma Group Ltd Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Mayne Pharma Group Ltd. The current atr is 0.25852992.

Mayne Pharma Group Ltd Daily Average True Range (ATR) ChartMayne Pharma Group Ltd Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Mayne Pharma Group Ltd. The current obv is -2,710,819.

Mayne Pharma Group Ltd Daily On-Balance Volume (OBV) ChartMayne Pharma Group Ltd Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Mayne Pharma Group Ltd. The current mfi is 50.42.

The long score for the Money Flow Index (MFI) is 1/2.
The longshort score for the Money Flow Index (MFI) is 1/(-2 +2).

  • MFI > 50: +1
Mayne Pharma Group Ltd Daily Money Flow Index (MFI) ChartMayne Pharma Group Ltd Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Mayne Pharma Group Ltd.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-09STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-10STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-11-14STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-16STOCH SHORT EXITThe %K line crosses above the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-11-17STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-20MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-11-21STOCH SHORT EXITThe %K line crosses above the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2023-11-22STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-23RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2023-11-24STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-11-30STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-01STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-04STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-06STOCH SHORT EXITThe %K line crosses above the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-08STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-12SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2023-12-14SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-15MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-19STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-20CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-12-21MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2023-12-22STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-27MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-28STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-29RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2024-01-03SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-05WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-08DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-01-09DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-10CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-11DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-12CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-15STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-16STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-01-18STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-22STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-23STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-24MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-01-25SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-01-30STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-01STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-07MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-02-08DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-09STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-13STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-02-14DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-02-16STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-19CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-20STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-21MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-02-22MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-23MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-26MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-27ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-01STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-04STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-05MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-03-07STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-12STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-14RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-15MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-03-19STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-21STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-27STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-28SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.

6.3. Candlestick Patterns

Mayne Pharma Group Ltd Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Mayne Pharma Group Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5069.113
Ma 20Greater thanMa 506.965
Ma 50Greater thanMa 1006.061
Ma 100Greater thanMa 2005.702
OpenGreater thanClose7.300
Total5/5 (100.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Mayne Pharma Group Ltd with someone you think should read this too:
  • Are you bullish or bearish on Mayne Pharma Group Ltd? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Mayne Pharma Group Ltd? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Mayne Pharma Group Ltd

I send you an email if I find something interesting about Mayne Pharma Group Ltd.


Comments

How you think about this?

Leave a comment

Stay informed about Mayne Pharma Group Ltd.

Receive notifications about Mayne Pharma Group Ltd in your mailbox!